1 / 10

Influenza Virus Vaccine 2012-2013 Strain Selection

Influenza Virus Vaccine 2012-2013 Strain Selection. Vaccines and Related Biological Products Advisory Committee (2/28/2012) Jerry P. Weir, Ph.D., Director Division of Viral Products/OVRR/CBER/FDA. Purpose of Today’s VRBPAC Committee Discussion.

cambria
Download Presentation

Influenza Virus Vaccine 2012-2013 Strain Selection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Influenza Virus Vaccine2012-2013 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2012) Jerry P. Weir, Ph.D., Director Division of Viral Products/OVRR/CBER/FDA

  2. Purpose of Today’s VRBPAC Committee Discussion • Review influenza surveillance and epidemiology data, antigenic characteristics of recent virus isolates, serological responses to current vaccines, and the availability of candidate vaccine strains and reagents • Make recommendations for the strains of influenza A (H1N1 and H3N2) and B viruses to be included in 2012-2013 influenza vaccines for use in the United States

  3. Types of Analyses Used forVaccine Strain Selection • Epidemiology of circulating strains (CDC) • Surveillance data from U.S. and around the world • Antigenic relationships among contemporary viruses and candidate vaccine strains (CDC/DOD/CBER) • Hemagglutination inhibition (HI) tests using post-infection ferret sera • HI tests using panels of sera from humans receiving TIV • Virus neutralization tests • Antigenic cartography • Phylogenetic analyses of HA and NA genes • Vaccine effectiveness

  4. Key Challenges for Vaccine Strain Selection • Vaccine effectiveness depends on match between the hemagglutinin (HA) of the vaccine and the HA of circulating strains of virus • Antigenic drift of HA continuous for influenza A and B • Antibody to HA correlated with vaccine efficacy • Timelines for influenza vaccine production are relatively fixed • Strain selection in February necessary for availability of vaccine for subsequent northern hemisphere winter (influenza season) • Manufacturers typically begin production of one monovalent before strain selection recommendations are made (at risk) • Availability of reference strains suitable for vaccine manufacture • Vaccine production depends on growth properties of strains used for manufacture • Strain-specific reagents needed for potency determination (inactivated vaccines)

  5. Considerations for the Development of Quadrivalent Seasonal Influenza Vaccines • Two antigenically distinct lineages of influenza B co-circulate • Represented by B/Victoria/2/87 and B/Yamagata/16/88 • Quadrivalent influenza vaccines containing 2 B strains (one from each lineage) are relatively far along in development • Manufacturers can provide updates • Unique challenges • B viruses typically slow growing (hg reassortants not available) • Additional reagents needed • Relatedness between 2 lineages makes SRID and identity testing difficult • Process for selecting appropriate B strains for inclusion in trivalent and quadrivalent vaccines should follow the current process of strain selection • WHO and VRBPAC review and recommendations • All trivalent vaccines should contain same B vaccine strain • Decision regarding inclusion of a 2nd B strain should be data driven

  6. 2011-2012 Seasonal Influenza Vaccine Strain Composition • VRBPAC strain selection – 2/22/2011 • Committee recommended the following strains for inclusion in U.S. 2010-2011 trivalent influenza vaccines • A/California/7/2009 (H1N1)-like virus • No change from the 2010-2011 vaccine recommendation • A/Perth/16/2009 (H3N2)-like virus • No change from the 2010-2011 vaccine recommendation • B/Brisbane/60/2008-like virus (B/Victoria lineage) • No change from 2010-2011 vaccine recommendation

  7. WHO Recommendations for Influenza Vaccine CompositionNorthern Hemisphere: 2012-2013 • Recommended that the following viruses be used for influenza vaccines in the 2012-2013 influenza season (NH winter): • an A/California/7/2009 (H1N1) pdm09 - like virus • an A/Victoria/361/2011 (H3N2) - like virus • B/Wisconsin/1/2010 - like virus (B/Yamagata lineage) • For those considering the use of a B/Victoria/2/87 lineage vaccine virus, either in trivalent vaccines or in quadrivalent vaccines containing two influenza B viruses, B/Brisbane/60/2008-like viruses continue to be the appropriate vaccine virus • As in previous years, national or regional control authorities approve the composition and formulation of vaccines used in each country

  8. Committee Discussion • Which influenza strains should be recommended for the antigenic composition of the 2012-2013 influenza virus vaccine in the U.S.? • Data to be considered includes: • the epidemiology of circulating influenza viruses • the antigenic characteristics of influenza virus strains currently circulating in human populations • the serologic responses to circulating influenza viruses of persons immunized with current influenza virus vaccines • manufacturing considerations including the availability of suitable vaccine candidate strains

  9. Options for Strain Composition for 2012-2013 Trivalent Influenza Vaccines • Influenza A (H1N1) • Retain current vaccine strain A/California/7/2009 (H1N1)-like virus • Replace current vaccine strain with an alternative vaccine virus • Influenza A (H3N2) • Replace current vaccine strain with an A/Victoria/361/2011 (H3N2) - like virus • Replace current vaccine strain with another candidate vaccine virus or retain current vaccine strain A/Perth/16/2009 (H3N2)-like virus • Influenza B • Replace current vaccine strain with B/Wisconsin/1/2010 - like virus (B/Yamagata lineage) • Replace current vaccine strain with another candidate vaccine virus or retain current B/Brisbane/60/2008-like virus (B/Victoria lineage)

  10. Options for Strain Selection for the 2nd Influenza B Strain in a Quadrivalent Influenza Vaccine • Influenza B • Include current vaccine strain B/Brisbane/60/2008-like virus (B/Victoria lineage) • Include another candidate vaccine virus of the B/Victoria lineage

More Related